Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul;40(3):576-587.
doi: 10.1007/s12928-025-01137-2. Epub 2025 May 30.

Feasibility of optical coherence tomography-guided primary percutaneous coronary intervention for STEMI: all-comer ATLAS-OCT trial

Affiliations
Observational Study

Feasibility of optical coherence tomography-guided primary percutaneous coronary intervention for STEMI: all-comer ATLAS-OCT trial

Kohei Wakabayashi et al. Cardiovasc Interv Ther. 2025 Jul.

Abstract

Intravascular imaging for acute coronary syndrome is recommended in the guidelines; however, the actual rate of patients with ST-segment elevation myocardial infarction (STEMI) who successfully undergo optical coherence tomography (OCT)-guided primary percutaneous coronary intervention (PCI) is unclear. This study aimed to determine the feasibility of OCT-guided primary PCI and identify the patient population that would benefit most from OCT guidance in STEMI. The ATLAS-OCT trial was a prospective, single-arm, all-comers study conducted at 16 institutions. The primary endpoint was the feasibility of OCT guidance for primary PCI, defined as successful image acquisition (vessel's circumferential or > 270° visualization along > 70% of the lesion's length, as evaluated by an independent core laboratory). A total of 632 patients (mean age: 68.4 years; 80.2% male) were enrolled in the study. OCT-guided PCI was performed in 503 patients, whereas OCT guidance was avoided in 129 patients for patient's condition. Successful image acquisition was achieved in all but seven patients who underwent OCT. The primary endpoint was achieved in 78.5% (496/632) of patients. No procedural complications were associated with OCT. Patients with left main disease (adjusted odds ratio, 4.1; 95% confidence interval, 1.2-14.7; p = 0.024), estimated glomerular filtration rate (mL/min/1.73 m2) < 30 (3.7; 1.6-8.3; p = 0.002), and Killip IV (2.5; 1.3-4.6; p = 0.003) were significantly avoided for OCT guidance. OCT guidance was feasible in four-fifths of all-comers with STEMI. Further studies are warranted to evaluate the efficacy of OCT-guided PCI in selected patient populations based on the findings of this trial (UMIN000048590).

Keywords: All-comers study; Optical coherence tomography; Percutaneous coronary intervention; ST-segment elevation myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Dr. Taishi Yonetsu received a research grant from CANON Medical Systems. Dr. Takuya Mizukami received consultancy fees from Zeon Medical Inc., research grants from Boston Scientific, and speaker fees from Abbott Vascular, Cathworks, and Boston Scientific. Dr. Koki Shishido received remuneration for lecture from Abbott Medical Japan LLC. Dr. Yoshiyasu Minami received remuneration for lecture and consultant fee from Abbott Medical Japan LLC. Dr. Takumi Higuma received scholarship funds from Abbott Medical Japan LLC. Dr. Satoru Suwa received personal fees from Abbott Medical Japan and Daiichi Sankyo LLC. Junya Ako received a speaking honorarium from Abbott Medical Japan LLC. Teruyoshi Kume received a speaking honorarium from Abbott Vascular Japan LLC. Dr. Shiro Uemura received a speaking honorarium and research grant from Abbott Vascular Japan LLC. Dr. Hiroyuki Okura received scholarship funds from Abbott Medical Japan LLC. Dr. Mamoru Nanasato received remuneration for lecture from Abbott Medical Japan LLC. Dr. Hiromasa Otake received research grants from Abbott Medical Japan LLC. Dr. Toshiro Shinke received personal fees and research grants from Abbott Medical Japan LLC. The remaining authors have no disclosures to report.

References

    1. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949–56. - DOI - PubMed
    1. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21–129. - DOI - PubMed
    1. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411–21. - DOI - PubMed
    1. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, Remkes W, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomized clinical trials. Lancet. 2019;393:2503–10. - DOI - PubMed
    1. Stone GW, Christiansen EH, Ali ZA, Andreasen LN, Maehara A, Ahmad Y, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet. 2024;403:824–37. - DOI - PubMed

Publication types

LinkOut - more resources